https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0716-10182012000500001
Quimioprofilaxis en niños y adultos sometidos a trasplante de órganos sólidos y precursores hematopoyéticos: Recomendaciones del Comité de Infecciones en Inmunocomprometidos Sociedad Chilena de Infectología. 2011

Rev Chilena Infectol 2012; 29 (Supl 1): 8-9

SUPLEMENTO

 

Quimioprofilaxis en niños y adultos sometidos a trasplante de órganos sólidos y precursores hematopoyéticos. Recomendaciones del Comité de Infecciones en Inmunocomprometidos Sociedad Chilena de Infectología. 2011

Chemoprophylaxis in children and adults undergoing solid organ and hematopoietic stem cells transplantation. Recommendations of The Committee of Infections in Immunocompromised Patients of the Chilean Society of Infectious Diseases. 2011

 

Coordinadora: M. Pilar Gambra A.

 

Integrantes del consenso (en orden alfabético)

Alba G., Andrea Unidad de Segunda Infancia Hospital Dr. Luis Calvo Mackenna, Santiago.

Álvarez P., AnaM. Servicio de Pediatría Hospital San Juan de Dios, Santiago.

Avilés L., Carmen L. Departamento de Pediatría Hospital San Borja-Arriarán Facultad de Medicina, Universidad de Chile, Santiago.

Benítez G., Rosana Servicio de Medicina Hospital DIPRECA, Santiago.

Bidart H., Teresa Unidad de Infectología Clínica Santa María, Santiago.

Catalán M., Paula Unidad de Trasplante de Precursores Hematopoyéticos Hospital Dr. Luis Calvo Mackenna, Santiago.

Ferrés G., Marcela Laboratorio de Infectología y Virología Molecular Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago.

Gambra A., M. Pilar Unidad de Infectología, Hospital Barros Luco Trudeau, Santiago. Facultad de Medicina, Universidad de Chile, Santiago.

Lafourcade R., Mónica Laboratorio de Microbiología Clínica Santa María, Santiago.

Nervi N., Bruno Departamento de Oncología Escuela de Medicina Pontificia Universidad Católica de Chile, Santiago.

Noemí H., Isabel Departamento de Pediatría Hospital Dr. Luis Calvo Mackenna, Santiago. Facultad de Medicina, Universidad de Chile.

Payá G., Ernesto Servicio de Pediatría Hospital de Carabineros Universidad Mayor, Santiago.

Rabagliati B., Ricardo Departamento de Enfermedades Infecciosas, Escuela de Medicina Pontificia Universidad Católica de Chile, Santiago.

Ramírez V., Pablo Departamento de Oncología Escuela de Medicina Pontificia Universidad Católica de Chile, Santiago.

Santolaya de P., M. Elena Unidad de Infectología Hospital Dr. Luis Calvo Mackenna, Santiago. Facultad de Medicina, Universidad de Chile.

Tassara O., Renzo Departamento de Pediatría Hospital San Juan de Dios, Santiago Facultad de Medicina, Universidad de Chile.

Zubieta A., Marcela Servicio de Pediatría Hospital Exequiel González Cortés, Santiago.

 

Introducción

El envejecimiento de la población y el avance de la medicina han permitido que el trasplante de órganos sólidos y precursores hematopoyéticos sean parte de la atención de un número creciente de personas. El trasplante predispone a infecciones dependiendo del órgano trasplantado, la inmunosupresión requerida, de la situación particular del binomio donante-receptor así como de la realidad epidemiológica del país. Las infecciones en el paciente trasplantado pueden comprometer tanto la viabilidad del trasplante como la vida del paciente. La complejidad de las medidas de prevención sugeridas o establecidas en la literatura científica generan confusión en los profesionales de atención de salud, por lo que surgió la necesidad de realizar recomendaciones que permitan estandarizar las opciones de prevención farmacológicas disponibles en la actualidad y adaptarlas a la realidad nacional. Estas recomendaciones representan una guía basada en la evidencia y revisan la epidemiología, factores de riesgo y medidas de prevención farmacológicas de enfermedades fúngicas, virales, parasitarias y micobacterianas más importantes en pacientes adultos y pediátricos sometidos a trasplantes de órganos sólidos y precursores hematopoyéticos. El siguiente documento pretende asistir al médico en la toma de decisiones prácticas, válidas, reproducibles y clínicamente flexibles en relación a quimioprofilaxis (QP) pre y post-trasplante.

Metodología. Se constituyó un panel de médicos expertos en microbiología clínica, infectólogos de adultos y niños, especialistas en trasplante de órganos sólidos (TOS) y trasplante de precursores hematopoyéticos (TPH).

Entre marzo y noviembre de 2010 este comité analizó la literatura científica publicada sobre QP en pacientes receptores de TOS y TPH, en idiomas inglés y español durante los últimos 10 años. Se realizó una búsqueda sistemática con los términos MESH: Transplant OR trasplant AND prophylaxis OR chemoprophylaxis, en los siguientes temas:

  • Hongos: Candida, hongos filamentosos, Pneumocystis jiroveci.   • Virus: citomegalovirus, virus de Epstein-Barr, adeno-virus, virus influenza, virus respiratorio sincicial.   • Parásitos: Toxoplasma gondii, Trypanosoma cruzi (enfermedad de Chagas).   • Micobacterias: Mycobacterium tuberculosis.   En cada área temática se intentó responder las interrogantes relacionadas a: epidemiología, factores de riesgo, eficacia de la quimioprofilaxis, fármacos empleados y dosis, duración de la QP y seguimiento. Se clasificó las recomendaciones según la calidad y fuerza de la evidencia (Tabla anexa).   Clasificación de grados de recomendación y calidad de la evidencia utilizados*     

María Pilar Gambra Acle     Coordinadora pilargambra@yahoo.es   Introduction Aging of the population and medical advances have made   solid organ and hematopoietic stem cells transplants part of the care of a   growing number of people. Transplant predisposes to infection depending on its   type, immuno-suppression required, donor-recipient conditions, as well as the   epidemiological situation in the country. Infections in these patients can   compromise both viability of the transplant itself as the patient's life. The   complexity of prevention can generate confusion in health care personnel. For   this reason, it is necessary to make recommendations standardizing currently   available pharmacological prevention options and adapt them to our national   reality. These evidence based guidelines review the epidemiology, risk factors   and pharmacological prevention measures for the most important fungal, viral,   parasitic and mycobacterial diseases in solid organ and hematopoietic stem cells   transplants, both in adults and children. Methods. Ain Expert   Committee of microbiologists, infectious diseases specialists, solid organs and   hematopoie-tic stem cells transplantation specialists was   constituted. From March to November 2010 this Committee reviewed and   analyzed scientific publications available about chemoprophylaxis for receptors of solid organ and   hematopoietic stem cells transplants. Established limits for this review were   articles published during last ten years in English or Spanish languages.   Utilized MESH terms were: Transplant OR trasplant AND prophylaxis OR chemoprophylaxis, in the following   topics:   • Fungus: Candida, molds, Pneumocystis   jiroveci.   • Virus: citomegalovirus, Epstein-Barr virus, adenovirus,   influenza virus, respiratory syncytial virus.   •  Parasites: Toxoplasma gondii, Trypanosoma cruzi (Chagas disease).   • Mycobacteria: Mycobacterium   tuberculosis.   For each microorganism the following aspects were searched   in order to answer queries related to: epidemiology, risk factors,   chemoprophylaxis efficacy, drugs and schedules recommended and follow   up. Each recommendation was classified according to the   scientific quality of the evidence and the emphasis done to this   recommendation. María Pilar Gambra Acle     Coordinadora pilargambra@yahoo.es 



En cada área temática se intentó responder las interrogantes relacionadas a: epidemiología, factores de riesgo, eficacia de la quimioprofilaxis, fármacos empleados y dosis, duración de la QP y seguimiento.

Se clasificó las recomendaciones según la calidad y fuerza de la evidencia (Tabla anexa).

  Clasificación de grados de recomendación y calidad de la evidencia utilizados*     

María Pilar Gambra Acle     Coordinadora pilargambra@yahoo.es   Introduction Aging of the population and medical advances have made   solid organ and hematopoietic stem cells transplants part of the care of a   growing number of people. Transplant predisposes to infection depending on its   type, immuno-suppression required, donor-recipient conditions, as well as the   epidemiological situation in the country. Infections in these patients can   compromise both viability of the transplant itself as the patient's life. The   complexity of prevention can generate confusion in health care personnel. For   this reason, it is necessary to make recommendations standardizing currently   available pharmacological prevention options and adapt them to our national   reality. These evidence based guidelines review the epidemiology, risk factors   and pharmacological prevention measures for the most important fungal, viral,   parasitic and mycobacterial diseases in solid organ and hematopoietic stem cells   transplants, both in adults and children. Methods. Ain Expert   Committee of microbiologists, infectious diseases specialists, solid organs and   hematopoie-tic stem cells transplantation specialists was   constituted. From March to November 2010 this Committee reviewed and   analyzed scientific publications available about chemoprophylaxis for receptors of solid organ and   hematopoietic stem cells transplants. Established limits for this review were   articles published during last ten years in English or Spanish languages.   Utilized MESH terms were: Transplant OR trasplant AND prophylaxis OR chemoprophylaxis, in the following   topics:   • Fungus: Candida, molds, Pneumocystis   jiroveci.   • Virus: citomegalovirus, Epstein-Barr virus, adenovirus,   influenza virus, respiratory syncytial virus.   •  Parasites: Toxoplasma gondii, Trypanosoma cruzi (Chagas disease).   • Mycobacteria: Mycobacterium   tuberculosis.   For each microorganism the following aspects were searched   in order to answer queries related to: epidemiology, risk factors,   chemoprophylaxis efficacy, drugs and schedules recommended and follow   up. Each recommendation was classified according to the   scientific quality of the evidence and the emphasis done to this   recommendation. María Pilar Gambra Acle     Coordinadora pilargambra@yahoo.es 



María Pilar Gambra Acle     Coordinadora pilargambra@yahoo.es

 

Introduction

Aging of the population and medical advances have made   solid organ and hematopoietic stem cells transplants part of the care of a   growing number of people. Transplant predisposes to infection depending on its   type, immuno-suppression required, donor-recipient conditions, as well as the   epidemiological situation in the country. Infections in these patients can   compromise both viability of the transplant itself as the patient's life. The   complexity of prevention can generate confusion in health care personnel. For   this reason, it is necessary to make recommendations standardizing currently   available pharmacological prevention options and adapt them to our national   reality. These evidence based guidelines review the epidemiology, risk factors   and pharmacological prevention measures for the most important fungal, viral,   parasitic and mycobacterial diseases in solid organ and hematopoietic stem cells   transplants, both in adults and children.

Methods. Ain Expert   Committee of microbiologists, infectious diseases specialists, solid organs and   hematopoie-tic stem cells transplantation specialists was   constituted.

From March to November 2010 this Committee reviewed and   analyzed scientific publications available about chemoprophylaxis for receptors of solid organ and   hematopoietic stem cells transplants. Established limits for this review were   articles published during last ten years in English or Spanish languages.   Utilized MESH terms were: Transplant OR trasplant AND prophylaxis OR chemoprophylaxis, in the following   topics:

  • Fungus: Candida, molds, Pneumocystis   jiroveci.   • Virus: citomegalovirus, Epstein-Barr virus, adenovirus,   influenza virus, respiratory syncytial virus.   •  Parasites: Toxoplasma gondii, Trypanosoma cruzi (Chagas disease).   • Mycobacteria: Mycobacterium   tuberculosis.   For each microorganism the following aspects were searched   in order to answer queries related to: epidemiology, risk factors,   chemoprophylaxis efficacy, drugs and schedules recommended and follow   up. Each recommendation was classified according to the   scientific quality of the evidence and the emphasis done to this   recommendation. María Pilar Gambra Acle     Coordinadora pilargambra@yahoo.es 



For each microorganism the following aspects were searched   in order to answer queries related to: epidemiology, risk factors,   chemoprophylaxis efficacy, drugs and schedules recommended and follow   up.

Each recommendation was classified according to the   scientific quality of the evidence and the emphasis done to this   recommendation.

María Pilar Gambra Acle     Coordinadora pilargambra@yahoo.es
